Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013

E. Sbidian (1) , C. Hotz (1) , J. Seneschal (2) , A. Maruani (3) , F. Amelot (4) , F. Aubin (5) , C. Paul (4) , M. Beylot Barry (6) , P. Humbert (7, 8) , A. Dupuy (9, 10) , F. Caux (11) , N. Dupin (12) , P. Modiano (13) , P. Lepesant (13) , S. Ingen-Housz-Oro (14) , E. Mahé (15) , H. Bachelez (16) , O. Chosidow (14) , P. Wolkenstein (14, 1)

1 CHU Henri Mondor [Créteil]
2 Biothérapies des maladies génétiques et cancers
3 Hôpital Trousseau
4 UDEAR - Unité différenciation épidermique et auto-immunité rhumatoïde
5 CEF2P / CARCINO - Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181)
6 Histologie et Pathologie Moléculaire
7 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
8 Département de dermatologie
9 Service de Dermatologie [Rennes] = Dermatology [Rennes]
10 CIC - Centre d'Investigation Clinique [Rennes]
11 Hôpital Avicenne [AP-HP]
12 Hôpital Cochin [AP-HP]
13 GHICL - Groupement des Hôpitaux de l'Institut Catholique de Lille
14 UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12
15 Service de Dermatologie - Centre Hospitalier Victor Dupouy
16 Hôpital Saint-Louis

Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas. European recommendations are mainly based on expert opinion. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres. The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor α (anti-TNFα) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA), and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo. Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNFα drugs for HS. This article is protected by copyright. All rights reserved

Domaines: Sciences du Vivant [q-bio]; Dermatologie

E. Sbidian, C. Hotz, J. Seneschal, A. Maruani, F. Amelot, et al.. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. British Journal of Dermatology, 2016, 174 (3), pp.667-670. ⟨10.1111/bjd.14199⟩. ⟨hal-01207284⟩